A phase I trial and pharmacokinetic study of trabectedin (Yondelis, ET-743 [ecteinascidin]) in children and adolescents with relapsed or refractory solid tumors.

Trial Profile

A phase I trial and pharmacokinetic study of trabectedin (Yondelis, ET-743 [ecteinascidin]) in children and adolescents with relapsed or refractory solid tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Trabectedin (Primary) ; Filgrastim; Pegfilgrastim
  • Indications Brain cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Hepatic tumours; Neuroblastoma; Osteosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 05 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 05 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 15 Oct 2011 Actual end date (October 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top